Quanterix (QTRX)
Market Price (5/3/2026): $3.4 | Market Cap: $159.2 MilSector: Health Care | Industry: Life Sciences Tools & Services
Quanterix (QTRX)
Market Price (5/3/2026): $3.4Market Cap: $159.2 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -51% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -41% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more. | Weak multi-year price returns2Y Excs Rtn is -120%, 3Y Excs Rtn is -150% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -110 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -79% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 15% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -56%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -58% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -71% Key risksQTRX key risks include [1] a planned financial restatement caused by material weaknesses in internal controls, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -51% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -41% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -120%, 3Y Excs Rtn is -150% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -110 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -79% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 15% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -56%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -58% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -71% |
| Key risksQTRX key risks include [1] a planned financial restatement caused by material weaknesses in internal controls, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Quanterix reported a significant miss on its Q4 2025 earnings per share (EPS) on March 2, 2026. The company posted a loss of ($0.38) per share, falling short of the consensus analyst estimate of ($0.27) by ($0.11), representing a 40.74% negative surprise.
2. The company exhibited concerning financial health with negative margins and a bleak profit outlook. In Q4 2025, Quanterix recorded a negative return on equity of 23.96% and a negative net margin of 77.14%. Analysts have subsequently forecast an approximate -$1 EPS for both the current fiscal year and the next fiscal year.
Show more
Stock Movement Drivers
Fundamental Drivers
The -46.4% change in QTRX stock from 1/31/2026 to 5/2/2026 was primarily driven by a -49.3% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 5022026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.34 | 3.40 | -46.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 129 | 139 | 7.5% |
| P/S Multiple | 2.3 | 1.1 | -49.3% |
| Shares Outstanding (Mil) | 46 | 47 | -1.6% |
| Cumulative Contribution | -46.4% |
Market Drivers
1/31/2026 to 5/2/2026| Return | Correlation | |
|---|---|---|
| QTRX | -46.4% | |
| Market (SPY) | 3.6% | 42.3% |
| Sector (XLV) | -5.8% | 30.1% |
Fundamental Drivers
The -36.3% change in QTRX stock from 10/31/2025 to 5/2/2026 was primarily driven by a -31.3% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 5022026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.34 | 3.40 | -36.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 124 | 139 | 11.6% |
| P/S Multiple | 1.7 | 1.1 | -31.3% |
| Shares Outstanding (Mil) | 39 | 47 | -16.9% |
| Cumulative Contribution | -36.3% |
Market Drivers
10/31/2025 to 5/2/2026| Return | Correlation | |
|---|---|---|
| QTRX | -36.3% | |
| Market (SPY) | 5.5% | 35.6% |
| Sector (XLV) | 1.5% | 24.7% |
Fundamental Drivers
The -41.0% change in QTRX stock from 4/30/2025 to 5/2/2026 was primarily driven by a -30.0% change in the company's P/S Multiple.| (LTM values as of) | 4302025 | 5022026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.76 | 3.40 | -41.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 135 | 139 | 2.4% |
| P/S Multiple | 1.6 | 1.1 | -30.0% |
| Shares Outstanding (Mil) | 39 | 47 | -17.7% |
| Cumulative Contribution | -41.0% |
Market Drivers
4/30/2025 to 5/2/2026| Return | Correlation | |
|---|---|---|
| QTRX | -41.0% | |
| Market (SPY) | 30.4% | 30.9% |
| Sector (XLV) | 5.2% | 35.1% |
Fundamental Drivers
The -73.1% change in QTRX stock from 4/30/2023 to 5/2/2026 was primarily driven by a -74.4% change in the company's P/S Multiple.| (LTM values as of) | 4302023 | 5022026 | Change |
|---|---|---|---|
| Stock Price ($) | 12.64 | 3.40 | -73.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 105 | 139 | 32.1% |
| P/S Multiple | 4.5 | 1.1 | -74.4% |
| Shares Outstanding (Mil) | 37 | 47 | -20.6% |
| Cumulative Contribution | -73.1% |
Market Drivers
4/30/2023 to 5/2/2026| Return | Correlation | |
|---|---|---|
| QTRX | -73.1% | |
| Market (SPY) | 78.7% | 34.1% |
| Sector (XLV) | 14.3% | 34.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| QTRX Return | -9% | -67% | 97% | -61% | -40% | -51% | -93% |
| Peers Return | 21% | -49% | 22% | -20% | -5% | -5% | -45% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 5% | 92% |
Monthly Win Rates [3] | |||||||
| QTRX Win Rate | 50% | 42% | 83% | 25% | 25% | 25% | |
| Peers Win Rate | 60% | 33% | 57% | 38% | 53% | 45% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| QTRX Max Drawdown | -19% | -82% | -27% | -63% | -60% | -52% | |
| Peers Max Drawdown | -11% | -57% | -20% | -31% | -38% | -17% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: LAB, BIO, TECH, TXG, TMO. See QTRX Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/1/2026 (YTD)
How Low Can It Go
| Event | QTRX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -45.2% | -18.8% |
| % Gain to Breakeven | 82.5% | 23.1% |
| Time to Breakeven | 240 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -17.8% | -7.8% |
| % Gain to Breakeven | 21.6% | 8.5% |
| Time to Breakeven | 10 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -16.1% | -9.5% |
| % Gain to Breakeven | 19.2% | 10.5% |
| Time to Breakeven | 32 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -25.5% | -6.7% |
| % Gain to Breakeven | 34.2% | 7.1% |
| Time to Breakeven | 16 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -61.1% | -33.7% |
| % Gain to Breakeven | 157.1% | 50.9% |
| Time to Breakeven | 121 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -19.1% | -19.2% |
| % Gain to Breakeven | 23.7% | 23.7% |
| Time to Breakeven | 57 days | 105 days |
In The Past
Quanterix's stock fell -45.2% during the 2025 US Tariff Shock. Such a loss loss requires a 82.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | QTRX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -45.2% | -18.8% |
| % Gain to Breakeven | 82.5% | 23.1% |
| Time to Breakeven | 240 days | 79 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -25.5% | -6.7% |
| % Gain to Breakeven | 34.2% | 7.1% |
| Time to Breakeven | 16 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -61.1% | -33.7% |
| % Gain to Breakeven | 157.1% | 50.9% |
| Time to Breakeven | 121 days | 140 days |
In The Past
Quanterix's stock fell -45.2% during the 2025 US Tariff Shock. Such a loss loss requires a 82.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Quanterix (QTRX)
AI Analysis | Feedback
Here are 1-3 brief analogies to describe Quanterix:
- They're like Illumina, but for ultra-sensitive protein detection and biomarker analysis instead of DNA sequencing.
- Imagine a specialized Thermo Fisher Scientific that focuses entirely on developing ultra-sensitive instruments and assays to detect minute amounts of disease-related biomarkers.
AI Analysis | Feedback
```html- HD-X Instrument: A sensitive, automated platform for multiplex protein detection.
- SR-X Instrument: An instrument that applies Simoa detection technology for various applications, including direct nucleic acid detection.
- SP-X Instrument: A platform based on Simoa planar array technology for measuring multiplex chemiluminescent immunoassays.
- Assay Kits & Consumables: Complementary kits, reagents, and other consumables essential for use with their immunoassay platforms.
- Contract Research Services: Services encompassing sample testing, homebrew assay development, and custom development to support life sciences research.
AI Analysis | Feedback
Major Customers of Quanterix (QTRX)
Based on the provided description, Quanterix sells its products and services primarily to organizations within the life science research sector. While specific customer names are not listed in the background information, its major customer categories include:
- Academic and Governmental Research Institutions: This category encompasses laboratories associated with universities, colleges, and various governmental research agencies.
- Pharmaceutical and Biotechnology Companies: These are companies involved in the research, development, and manufacturing of drugs and biological products.
- Contract Research Organizations (CROs): These companies provide research services on a contract basis to the pharmaceutical, biotechnology, and medical device industries.
AI Analysis | Feedback
null
AI Analysis | Feedback
Here is the management team of Quanterix (QTRX):Everett Cunningham, President and Chief Executive Officer
Everett Cunningham was appointed President and Chief Executive Officer of Quanterix, effective January 19, 2026. Prior to joining Quanterix, he served as Chief Commercial Officer at Illumina since June 2024, where he was responsible for the company's global commercial strategy and execution. During his tenure at Illumina, he helped implement a redesigned commercial operating model. Before Illumina, Mr. Cunningham was Chief Commercial Officer at Exact Sciences, where he led marketing, sales, and customer service for their cancer screening and precision oncology diagnostics portfolio. He also held senior leadership positions at Quest Diagnostics, GE Healthcare, and Pfizer.
Vandana Sriram, Chief Financial Officer
Vandana Sriram is the Chief Financial Officer of Quanterix. Her insider holdings at Quanterix were reported in February 2026.
AI Analysis | Feedback
Here are the key risks to Quanterix's business:
- Reliance on Single-Source Contract Manufacturers: Quanterix is significantly exposed to supply chain risk due to its dependence on single-source contract manufacturers, including STRATEC, Paramit, and Columbia Tech, for the production of its critical Simoa HD-X, SR-X, PhenoCycler, and PhenoImager instruments. Any failure, delay, or quantity shortfall from these manufacturers or their own limited suppliers could materially disrupt instrument supply, adversely affecting Quanterix's business, financial condition, operating results, and reputation.
- Market Headwinds and Profitability Challenges: The company faces ongoing market headwinds, including reduced funding in academic research and biopharma spending. This has contributed to revised revenue guidance and persistent net losses. While Quanterix aims to achieve cash flow breakeven in the second half of 2026, the path to sustained profitability remains uncertain, with the company recording significant losses in recent periods.
- Risk of Technological Obsolescence and Intense Competition: Operating in the rapidly innovating biotechnology sector, Quanterix faces the constant threat that its current Simoa technologies could become obsolete. Competitors may introduce more efficient or cost-effective diagnostic technologies, necessitating continuous investment in research and development to maintain its competitive edge.
AI Analysis | Feedback
nullAI Analysis | Feedback
Quanterix Corporation (QTRX) has significantly expanded its addressable market through strategic acquisitions. Following the acquisition of Akoya Biosciences in 2025, Quanterix's served addressable market expanded from an initial $1 billion to $5 billion. This expanded global market encompasses key therapeutic areas such as neurology, immunology, and oncology, and also extends to inflammation and infectious diseases, leveraging the combined capabilities of their Simoa and Spatial Biology platforms. In addition to its product platforms, Quanterix also offers contract research services. The global contract research organization (CRO) services market, which includes these services, was valued at approximately USD 77.0 billion in 2024. This market is projected to reach USD 162.1 billion by 2033, growing at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2033. North America held the largest share of the global CRO market, accounting for 35% in 2024. Oncology applications dominate the CRO services market, representing a 35.4% share in 2024.AI Analysis | Feedback
Quanterix Corporation (QTRX) is poised for future revenue growth over the next two to three years, driven by its strategic focus on key areas within precision health and life sciences research. The company's anticipated growth drivers include the commercialization of its Alzheimer's diagnostics, sustained expansion in consumables and assay sales, the successful integration of Akoya Biosciences and corresponding market penetration in spatial biology, and the broader adoption of its ultra-sensitive Simoa and spatial biology platforms.
One primary driver is the **advancement and commercialization of Alzheimer's diagnostics**. Quanterix is actively pursuing FDA approval for its Alzheimer's diagnostics, with significant growth targeted for 2027. The company reached key milestones in late 2025 and early 2026, including the Centers for Medicare & Medicaid Services (CMS) approving a reimbursement rate of $897 for its LucentAD Complete test, and the submission of a 510(k) premarket notification to the FDA for the same test in January 2026.
Secondly, **continued growth in consumables and assay sales** is expected to fuel revenue. Consumables demonstrated strong performance in Q4 2025, and Quanterix anticipates this trend to persist. By the end of 2025, recurring revenue, largely from consumables, constituted approximately 75% of the total revenue, indicating a stable and growing base.
A third significant driver is the **strategic integration of Akoya Biosciences and expansion into spatial biology**. The acquisition of Akoya Biosciences expanded Quanterix's portfolio, creating an integrated platform for biomarker analysis across both blood (Simoa) and tissue (spatial biology). The company is on track to realize planned cost synergies from this integration, with the remaining synergies expected to be captured by the end of Q1 2026. This expanded offering allows Quanterix to address new markets and applications.
Lastly, **broadening adoption of Simoa and spatial biology platforms** is critical for future revenue. Quanterix has seen accelerating scientific validation and publication activity, with cumulative publications reaching over 6,300 by year-end 2025, reflecting increasing researcher adoption of both its Simoa and spatial biology technologies. The company is focused on deepening customer and partner relationships, which is expected to drive further utilization and placement of its instruments.
AI Analysis | Feedback
Share Repurchases
- Quanterix repurchased $1.45 million in common stock in 2025.
- The company repurchased $2.61 million in common stock in 2024.
- In 2023, share repurchases amounted to $0.2 million.
Share Issuance
- In February 2021, Quanterix completed a public offering of 4,107,142 shares of common stock at $70.00 per share, generating approximately $287.5 million in gross proceeds.
- As part of the Akoya Biosciences acquisition in July 2025, Quanterix offered 7.8 million shares to Akoya's investors.
- Proceeds from common stock issued under stock plans were $0.74 million in 2025, a decrease from $3.07 million in 2024, and $2.89 million in 2023.
Outbound Investments
- Quanterix acquired Akoya Biosciences in July 2025, an investment that included 7.8 million shares offered and $20 million paid, aiming to add integrated spatial biology capabilities and diversify revenue streams.
- In January 2025, Quanterix acquired Emission, Inc. for an upfront payment of $10.0 million, with potential additional payments of $10.0 million upon technical milestones and up to $50.0 million in earnout payments through December 31, 2029.
- The company has implemented $74 million of an $85 million cost-synergy target related to the Akoya acquisition by the end of 2025, with full realization expected by the first quarter of 2026.
Capital Expenditures
- Quanterix's capital expenditures were $2.61 million in 2025, $3.37 million in 2024, $3.84 million in 2023, $11.61 million in 2022, and $13.68 million in 2021.
- Capital expenditures are primarily focused on purchasing equipment to support the company's infrastructure and enhancing product offerings, including the planned launch of the next-generation Simoa ONE instrument by the end of 2025.
- The company expects to incur additional capital expenditures in future periods to support these efforts and aims to achieve cash flow breakeven in the second half of 2026.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to QTRX.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 38.73 |
| Mkt Cap | 4.9 |
| Rev LTM | 929 |
| Op Inc LTM | 65 |
| FCF LTM | 177 |
| FCF 3Y Avg | 127 |
| CFO LTM | 193 |
| CFO 3Y Avg | 160 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 2.1% |
| Rev Chg 3Y Avg | 2.9% |
| Rev Chg Q | 0.9% |
| QoQ Delta Rev Chg LTM | 0.2% |
| Op Inc Chg LTM | 4.0% |
| Op Inc Chg 3Y Avg | -5.0% |
| Op Mgn LTM | -4.2% |
| Op Mgn 3Y Avg | -8.5% |
| QoQ Delta Op Mgn LTM | 0.3% |
| CFO/Rev LTM | 19.0% |
| CFO/Rev 3Y Avg | 12.2% |
| FCF/Rev LTM | 14.4% |
| FCF/Rev 3Y Avg | 7.1% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 4.9 |
| P/S | 3.6 |
| P/Op Inc | 9.9 |
| P/EBIT | 22.5 |
| P/E | 12.0 |
| P/CFO | 17.3 |
| Total Yield | 0.0% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 1.9% |
| D/E | 0.1 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -2.0% |
| 3M Rtn | -16.4% |
| 6M Rtn | -18.4% |
| 12M Rtn | 9.1% |
| 3Y Rtn | -41.2% |
| 1M Excs Rtn | -10.2% |
| 3M Excs Rtn | -20.6% |
| 6M Excs Rtn | -22.7% |
| 12M Excs Rtn | -22.4% |
| 3Y Excs Rtn | -120.5% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Single Segment | 137 | 122 | |||
| Collaboration and license revenue | 1 | 1 | 12 | ||
| Grant revenue | 1 | 5 | 6 | ||
| Product revenue | 70 | ||||
| Service revenue | 34 | ||||
| Consumable and other products | 55 | 27 | |||
| Instruments | 26 | 17 | |||
| Other services | 2 | 1 | |||
| Research services | 15 | 18 | |||
| Service-type warranties | 7 | 5 | |||
| Total | 137 | 122 | 106 | 111 | 86 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Single Segment | -39 | ||||
| Total | -39 |
Price Behavior
| Market Price | $3.40 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 12/07/2017 | |
| Distance from 52W High | -57.8% | |
| 50 Days | 200 Days | |
| DMA Price | $4.25 | $5.50 |
| DMA Trend | down | down |
| Distance from DMA | -20.1% | -38.2% |
| 3M | 1YR | |
| Volatility | 67.0% | 79.8% |
| Downside Capture | 2.19 | 1.18 |
| Upside Capture | 34.97 | 89.04 |
| Correlation (SPY) | 39.7% | 30.4% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.17 | 1.71 | 1.75 | 1.95 | 1.95 | 1.66 |
| Up Beta | 0.71 | 0.64 | 0.90 | 1.40 | 2.02 | 1.80 |
| Down Beta | 3.73 | 1.72 | 2.02 | 1.58 | 2.46 | 1.63 |
| Up Capture | 21% | -22% | 32% | 167% | 94% | 126% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 10 | 13 | 23 | 51 | 114 | 354 |
| Down Capture | 706% | 380% | 295% | 214% | 170% | 112% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 11 | 29 | 40 | 72 | 134 | 392 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with QTRX | |
|---|---|---|---|---|
| QTRX | -35.3% | 79.3% | -0.22 | - |
| Sector ETF (XLV) | 5.2% | 16.0% | 0.13 | 34.8% |
| Equity (SPY) | 30.6% | 12.5% | 1.88 | 30.4% |
| Gold (GLD) | 39.5% | 27.2% | 1.20 | 3.0% |
| Commodities (DBC) | 51.5% | 17.9% | 2.20 | -10.6% |
| Real Estate (VNQ) | 13.1% | 13.5% | 0.67 | 25.3% |
| Bitcoin (BTCUSD) | -17.1% | 42.2% | -0.33 | 16.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with QTRX | |
|---|---|---|---|---|
| QTRX | -43.6% | 79.2% | -0.35 | - |
| Sector ETF (XLV) | 5.0% | 14.6% | 0.17 | 35.7% |
| Equity (SPY) | 12.8% | 17.1% | 0.59 | 40.0% |
| Gold (GLD) | 20.5% | 17.9% | 0.94 | 5.7% |
| Commodities (DBC) | 14.3% | 19.1% | 0.61 | 4.1% |
| Real Estate (VNQ) | 3.5% | 18.8% | 0.09 | 35.7% |
| Bitcoin (BTCUSD) | 7.7% | 56.2% | 0.35 | 22.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with QTRX | |
|---|---|---|---|---|
| QTRX | -14.3% | 75.8% | 0.11 | - |
| Sector ETF (XLV) | 9.1% | 16.5% | 0.45 | 35.4% |
| Equity (SPY) | 14.9% | 17.9% | 0.71 | 39.0% |
| Gold (GLD) | 13.6% | 15.9% | 0.71 | 5.6% |
| Commodities (DBC) | 9.7% | 17.7% | 0.46 | 9.6% |
| Real Estate (VNQ) | 5.7% | 20.7% | 0.24 | 32.9% |
| Bitcoin (BTCUSD) | 67.7% | 66.9% | 1.07 | 15.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/2/2026 | -7.3% | -19.4% | -44.4% |
| 11/10/2025 | -2.3% | 8.0% | 47.5% |
| 8/7/2025 | -13.8% | -17.6% | -18.0% |
| 3/17/2025 | -1.8% | -1.2% | -26.4% |
| 11/12/2024 | -18.3% | -27.1% | -26.4% |
| 8/8/2024 | -14.8% | -11.5% | -6.5% |
| 5/7/2024 | -4.9% | -3.1% | -10.0% |
| 2/27/2024 | -3.7% | 11.9% | -12.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 8 | 8 |
| # Negative | 13 | 14 | 14 |
| Median Positive | 7.7% | 10.1% | 6.7% |
| Median Negative | -7.3% | -11.0% | -11.4% |
| Max Positive | 16.9% | 30.2% | 47.5% |
| Max Negative | -54.8% | -38.3% | -44.4% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/02/2026 | 10-K |
| 09/30/2025 | 11/10/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/12/2025 | 10-Q |
| 12/31/2024 | 03/17/2025 | 10-K |
| 09/30/2024 | 12/26/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/29/2024 | 10-K |
| 09/30/2023 | 11/08/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/06/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/08/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Sriram, Vandana | Chief Financial Officer | Direct | Buy | 9152025 | 4.79 | 4,150 | 19,878 | 417,688 | Form |
| 2 | Walt, David R | Direct | Buy | 6132025 | 6.14 | 123,990 | 760,803 | 11,455,501 | Form | |
| 3 | Walt, David R | Direct | Buy | 6132025 | 6.23 | 36,010 | 224,166 | 10,849,994 | Form | |
| 4 | Toloue, Masoud | President & CEO | Direct | Buy | 6102025 | 5.42 | 45,900 | 248,723 | 2,811,935 | Form |
| 5 | Walt, David R | Direct | Buy | 6092025 | 5.34 | 78,131 | 417,220 | 9,115,022 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.